Trial Profile
A Phase Ib/II Study of Venetoclax in Combination With Quizartinib in FLT3-Mutated Acute Myelogenous Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Quizartinib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2023 Status changed from active, no longer recruiting to completed.
- 13 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 13 Mar 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.